IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
NCT04482777 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90
Last updated 2023-08-09
Summary
To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP
Conditions
Interventions
- DRUG
-
Corticosteriod for treated patients
Drug given to some patients with autoimmune disease
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 2 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-30
- Primary Completion
- 2023-08-01
- Completion
- 2023-09-01
More Related Trials
-
High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
NCT05943691 ·Status: UNKNOWN ·Phase: PHASE2
-
Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia
NCT07182760 ·Status: NOT_YET_RECRUITING
-
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
NCT01356511 ·Status: COMPLETED ·Phase: PHASE4
-
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level
NCT03864796 ·Status: COMPLETED
-
Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
NCT07070193 ·Status: NOT_YET_RECRUITING
-
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
NCT06531018 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439 ·Status: UNKNOWN
-
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851 ·Status: RECRUITING ·Phase: PHASE2
-
Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP
NCT03998982 ·Status: UNKNOWN ·Phase: PHASE4
-
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
NCT04800458 ·Status: RECRUITING ·Phase: NA
-
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06094881 ·Status: RECRUITING ·Phase: PHASE2
-
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
NCT07268898 ·Status: NOT_YET_RECRUITING
-
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
NCT01317966 ·Status: WITHDRAWN
-
Atorvastatin in Management of Newly Diagnosed ITP
NCT03692754 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP
NCT05846529 ·Status: UNKNOWN
-
NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults
NCT01172015 ·Status: COMPLETED ·Phase: NA
-
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962 ·Status: RECRUITING ·Phase: PHASE2
-
Caffeic Acid Tablets as a Second-line Therapy for ITP
NCT02351622 ·Status: COMPLETED ·Phase: PHASE3
-
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
NCT04003220 ·Status: UNKNOWN
-
Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura
NCT04311593 ·Status: UNKNOWN
-
Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
NCT03771378 ·Status: UNKNOWN ·Phase: PHASE4
-
Anti-BCMA CAR T-Cell Therapy for R/R ITP
NCT05315778 ·Status: UNKNOWN ·Phase: PHASE2
-
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582 ·Status: RECRUITING
-
Immune Markers in Pediatric ITP on Second Line Therapy
NCT06093529 ·Status: NOT_YET_RECRUITING